Introduction
Renal alterations in patients with systemic lupus erythematosus (SLE) worsen their prognosis and quality of life 1 but, advances in last decades have fortunately allowed to better understand and treat acute kidney complications as well as those appear in the course of the disease. However, there is still a considerable number of resistant and recurrent episodes and very disturbing situations such as acute or subacute deterioration of renal function. 2 Health System. Novel aspects in areas of uncertainty related to lupus nephritis (LN) and extrarenal manifestations in which nephrologists can be involved are summarized in the present editorial. 3
Methods
The methodology followed to develop this CPG for SLE patients is detailed in the original publication. 3 The group conducted a process to identify and prioritize relevant topics to be addressed by the CPG, taking into account the relevant inputs from a Delphi consultation to people affected with SLE in Spain. Each selected clinical question were structured using the PICO format (Patients, Intervention, Comparison, Outcome). A systematic review of evidence was produced for each key question. The methodological quality of 2013-2514/© 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). previous GPCs was assessed with the AGREE II instrument and included systematic reviews and individual studies were assessed based on the Scottish Intercollegiate Guidelines Network (SIGN) criteria. The levels of evidence and grades of recommendations were also set according to SIGN criteria. For important practical aspects without scientific evidence available, good clinical practice recommendations ( √ ) were formulated and agreed by consensus of experts. The expert group consisted of 10-13 professionals based on the nature of each recommendation (rheumatology, internal medicine, hematology, dermatology, immunology, nephrology, gynecology, neurology, nursing and hospital pharmacy) ( Fig. 1 ).
This guideline addresses the following principal questions regarding LN:
Question n • 1. What dose of steroids would be more appropriate for the induction treatment? Under what conditions mycophenolate (MF) would provide advantages over other drugs?

Summary of evidence:
-Methylprednisolone pulse therapy at a dose of 0.5-0.75 g/day in three batches has shown similar effectiveness and fewer side effects than higher doses. 4 Level of evidence (LE) 3. -Initial doses of prednisone not exceeding 30 mg/day combined with hydroxychloroquine, immunosuppressants and/or methylprednisolone pulses lead to response rates at least similar to regimens with higher doses. 5,6 LE 1−/2+. -The accumulated dose and the number of weeks with prednisone dose > 5 mg/day are associated with an increased toxicity. 6 LE 2+. -Adverse effects of cyclophosphamide (CF) have led to the search for lower doses and alternative drugs with at least the same effectiveness. An accumulated dose of CF higher than 8 g increases the risk of ovarian failure. For older patients, the safety dose is reduced up to approximately 5 g. 7 LE 2+. -For Hispanics/Latin Americans and African Americans, MF has shown to be more effective than CF. 8 LE 1+. For induction therapy, the most commonly used dose of mycophenolate mofetil (MFM) in high quality studies is 2 g/day for mild to moderate NL in Europe and 3 g/day for more severe ones in North America. 9,10 LE 2+.
Recommendations:
-Pulse therapy with methylprednisolone is suggested in the more severe cases, with nephrotic syndrome and/or renal failure. It's also suggested as oral prednisone saver. Grade of Recommendation (GR): √ -It is suggested to start with doses of oral prednisone not higher than 30 mg/day. GR:C -The decrease in prednisone dosages should be quick till ≤5 mg/day. Reaching 5 mg/day around 3 months and not later than 6 months is recommended. GR:C -In women older than 30 years or at risk of ovarian failure, the use of low dose of cyclophosphamide (Euro-Lupus Nephritis Trial [ELNT] pattern) or choose mycophenolate for both induction and maintenance treatment is suggested. GR:C -In women of childbearing age who have received cyclophosphamide, reaching a cumulative dose higher than 8 g (or 5 g if older than 30 years), mycophenolate (or azathioprine) is suggested as first-line maintenance treatment in the current episode and as induction and maintenance treatment in successive episodes. GR:C -If therapeutic non-compliance is suspected, cyclophosphamide instead of mycophenolate is suggested. GR: √ -In Hispanic patients from Latin America and African Americans, the administration of mycophenolate is suggested. GR:C -The recommended dose of MFM in induction treatment is 2-3 g/day or equivalent doses of sodium MF. GR:B
Question n • 2: What should be the induction treatment for NL with acute kidney failure?
Summary of evidence: Overall, acute renal failure (ARF) is considered when an increment of serum creatinine >1.5-fold from baseline or an increment of 0.3 mg/dl within 48 h with or without oliguria is produced. 11 -The incidence of ARF is probably low but unknown or undetermined since most large studies have excluded these patients. Only case studies, case series and retrospective cohorts are available. ARF is associated with worse prognosis for long-term renal survival. 11 
Question n • 3. When the maintenance treatment should be suspended?
Summary of evidence: Clinical trials and cohort studies in which the minimum duration of therapy was 24-36 months have shown that the incidence of renal flare in NL despite the immunosuppressive treatment is high, ranging from 12 to 45% in the first 2-5 years. From five years, the occurrence of renal flares would be progressively smaller and unusual after 10 years of remisión. [19] [20] [21] [22] LE 1++/1+/2+.
-In proliferative LN, the occurrence of a renal flare is associated with a worse renal and patient survival. 22 Nephritic type is associated with worse renal survival than nephrotic type. 19, [23] [24] [25] However, in the membranous class, renal flare does not seem to influence renal survival. 25 LE 2+. -Extend the duration of maintenance treatment up to 30 months reduces the risk of early relapse and increases renal and patient survival. 20, 26 However, there are no clinical trials directly comparing longer or shorter treatment periods using the same therapeutic regimen. LE 1+/2+. (Table 1) , it seems justified to consider the withdrawal of maintenance treatment. 21,28 LE 2+. -In patients at high risk of relapse (Table 1) , an extension of the treatment for more than five years or even indefinitely is proposed unless it's contraindicated. 29 LE 4. -Before considering treatment withdrawal, it seems justified to complete a minimum of 12 months of quiescence. 21, 28, 30 LE 2+. -The termination of therapy must be very slowly. 21, 30 A close monitoring during the first five years, allowing early detection and treatment of renal flares, is associated to better long-term survival. 23 ,31 LE 2+.
Recommendations:
-Maintenance therapy is recommended for all patients who have achieved at least a partial response to induction. GR:A -It is recommended to extend this maintenance therapy for at least 2-3 years. GR:B -In patients with frequent recurrences without justifiable cause or risk factors for renal recurrence, it is suggested to extend maintenance therapy for at least five years. GR: √ -When considering the total withdrawal of immunosuppressive maintenance treatment, it should not be done before a period of clinical analytic quiescence shorter than 12 months. GR:C -The total suspension of maintenance immunosuppressive therapy should be carried out slowly and progressively. GR:C -Maintaining the long-term treatment with hydroxychloroquine is suggested, provided there are no contraindications or side effects for it. GR:C
Question n • 4. When a therapeutic regimen is considered ineffective? and a situation as refractory? How to manage it?
Summary of evidence: There is no standard definition for refractoriness. However, considering the prognostic significance of not getting a reduction of baseline proteinuria of more than 50% at six months or a total proteinuria 1 g/24 h, the absence of at least partial remission after six months of treatment has been proposed as the main criterion of inefficiency. Refractoriness is therefore defined as the absence of at least partial remission after six months of treatment. 32,33 LE 4.
-Therapeutic non-compliance is one of the first reasons to be discarded before considering a treatment as ineffective. This risk should be discussed with patients in their first visits. A suspected non-compliance may be one of the reasons to assess drug levels or to choose in proliferative classes induction regimens with intravenous CF pulses. 33,34 LE 4. -In refractory patients to standard immunosuppressive regimens (CF o MFM), tacrolimus monotherapy has been used with success and safety. 35 Also in combination with MFM, in a multi-targeted approach that allows increasing overall immunosuppression with fewer individual doses. 36 r e f e r e n c e s
